Genentech, a member of the Roche Group, has extended its exclusivity period for the research collaboration and license agreement with Phylogica Ltd. to discover novel antibiotics using Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.   Phylogica will receive a $2 million milestone payment. As previously announced in December 2014, Phylogica is eligible to receive research, development, and commercialization milestone p...